Skolkovo Foundation and AstraZeneca sign a strategic partnership agreement

| By | AstraZeneca, Cancer Drugs, Skolkovo

Skolkovo Foundation and AstraZeneca, an international biopharmaceutical company, have agreed on a strategic partnership in the area of research and educational activities in Russia.

The parties intend to implement a number of research and educational projects in Russia. Currently, AstraZeneca is studying the developments of the resident companies of Skolkovo in the area of oncology, for potential cooperation. The partnership of the parties in the area of oncology will continue within a joint project to develop an innovative mathematical modeling platform that can forecast the therapeutic potential of combining new oncological medicines and predict the results of clinical trials conducted by AstraZeneca in the area of immuno-oncology in Russia.

Irina Panarina, the General Director of AstraZeneca Russia & Eurasia, said, “Being a leader in science is the key priority for AstraZeneca. We operate in Russia for more than a decade and strive to make maximum contribution to the development of local research projects. We are happy to have such a partner as Skolkovo Foundation that fully shares our values and thinks in an innovative way. I am confident that expanding the areas of our joint work will open new prospects.”

VIArussian version
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.